Background Only few studies have compared health related quality of life (HRQoL) between rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients.
Objectives To compare the Medical Outcomes Survey Short Form-36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) in RA and PsA patients from a large prospective observational registry.
Methods We included RA and PsA patients from the prospective observational multicenter Norwegian-Disease-Modifying Antirheumatic Drug (NOR-DMARD) study, who started first-time tumour necrosis factor inhibitors or DMARD naïve patients starting methotrexate between year 2000 and 2012. Continuous variables were compared using independent t-test (normally distributed data). Prespecified ANCOVA analyses adjusted for age, gender and years since diagnosis were performed to compare SF-36 PCS and MCS between the RA and PsA patients at baseline and after 3 and 6 months follow-up.
Results A total of 2735 RA and 1236 PsA patients were included. Mean (SD) age was 55.0 (13.5)/ 48.3 (12.4) years, median (25th-75th percentile) years since diagnosis 0.7 (0.02–6.4)/ 1.3 (0.09–7.7), 69.7/48.4% were women and 31.7/29.8% current smokers. Mean (SD) 28-joint Disease Activity Score was higher in RA vs. PsA patients at baseline (4.9 (1.4)/ 4.2 (1.3)) and at 3 (3.6 (1.5)/ (3.1 (1.4)) and 6 months follow-up (3.3 (1.4)/ 3.0 (1.3)), respectively (p≤0.001). Unadjusted means (SD) of SF-36 PCS and MCS were similar between the RA and PsA patients (Table 1).
In adjusted analyses SF-36 PCS was slightly higher and SF-36 MCS similar between RA and PsA patients at 3 and 6 months follow-up (Table 2).
Conclusions Mental HRQoL reflected through SF-36 MCS was similar between RA and PsA patients at all time points, in spite of slightly worse physical HRQoL reflected through lower SF-36 PCS in the PsA group at 3 and 6 months follow-up.
Disclosure of Interest B. Michelsen: None declared, E. Lie Consultant for: Hospira, Pfizer, UCB, Speakers bureau: AbbVie, Celgene, K. Fagerli: None declared, E. Kristianslund: None declared, H. Hammer Consultant for: AbbVie, Pfizer, UCB, Roche, MSD, BMS and Novartis., Speakers bureau: AbbVie, Pfizer, UCB, Roche, MSD, BMS and Novartis., G. Haugeberg: None declared, T. Kvien Consultant for: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB, Speakers bureau: AbbVie, Biogen, BMS, Boehringer Ingelheim, Celltrion, Eli Lilly, Epirus, Janssen, Merck-Serono, MSD, Mundipharma, Novartis, Oktal, Orion Pharma, Hospira/Pfizer, Roche, Sandoz and UCB